Reference no: EM133542486 , Length: Words Count:500

Assignment:

People with type II diabetes have increased risk of cardiovascular morbidity and mortality. Does use of GLP-1 agonists to manage type II diabetes improve these risk factors and result in improved cardiovascular outcomes for patients?

In 500 words, discuss the evidence in order to attempt to answer the above questions. take the position where providing information from the literature such that the reader is able to make an informed decision on the use of GLP-1 agonists. As such the argument should be balanced and supported by evidence from the experimental literature.

• need to research the current literature to find information on the topic described to help answer the questions.
• Strong supporting evidence includes different types of experiments, across different cohorts or species. Depending on the topic this may be pre-clinical (animal) or clinical evidence.
• It considers the number of people (or animals) and whether outcomes have been replicated and/or similar results found. It may compare effects across drugs in the same class. It may consider effect size
• Demonstrates in depth knowledge of GLP-1 agonists and their approved uses. Demonstrates a sophisticated, nuanced understanding of the complexities of applying knowledge to emerging issues.
• Selects a discerning range of relevant and reliable sources and uses evidence found selectively; Effective associations made between the question and key concepts Clearly addresses the question with appropriate, clear and specific recommendations and thoroughly considers limitations and assumptions
• Requires reflection and inclusion of alternate points of view or contrasting information
• please include the reference